India's New Draft Biotech Patent Guidelines: What does it mean for Biotech Businesses?

I. Introduction:
On 4th September 2026, the Patent Office released the Draft Guidelines for Examination of Biotechnology Patent Applications, 2026. They were published alongside the draft guidelines for pharmaceutical patents. The Guidelines are supposed to guide Examiners and Controllers with patent examination and prosecution, and their main aim is to help them decide on patent applications uniformly and consistently. Their publication for the public, however, helps prospective patent applicants understand the thought process of the Examiners and make informed choices about patent drafting and patent strategy. It is important to note that the Guidelines add to the existing Manual of Patent Office Practice and Procedure; they do not replace it. The Draft Guidelines essentially codify patent examination practices which have developed over the last 15 years through patent examination, prosecution and court precedents.

II. Why even have new guidelines?
Patent applications in biotechnology have grown sharply over the past few decades. The Indian Patent Office last issued biotech examination guidelines in 2013. Since then, the science has moved fast; CRISPR-Cas9 gene editing and cell therapy are now real patentable products and not simply ideas or lab experiments. The old guidelines no longer suffice for such ever-evolving technology, and the examination process needed a fresh look. The new Draft Guidelines attempt to address this gap. While they may not fully address the concerns of the industry, they are certainly an attempt in the right direction.

III. So, what exactly is new?
The Draft replaces the generic examples of the old guidelines with clear, illustrative examples. Under the 2013 guidelines, applicants often could not predict how an Examiner would treat new technologies. The 2026 Draft is built around 36 worked examples, many showing why a biotech patent would be refused. They cover newer areas such as CRISPR-Cas9 and cell therapy. Businesses should now check their filings against these examples before the Examiner does, and accordingly be prepared for arguments in the Examiner's report.

Court decisions have also been written into the guidelines. Important Indian court rulings on biotech patents have emerged as the Indian Courts take higher cognizance of the ever-developing intellectual property rights. The Draft reproduces entire paragraphs from these rulings, for example DS Biopharma (2022) on Section 3(d) objections and Zero Brand Zone on traditional knowledge under Section 3(p). We believe that the Examiners are very likely to copy these paragraphs word for word into their First Examination Reports (FERs). Applicants should therefore expect these cases in objections and hearings.

Further, Examiners will now have to disclose their search strings. The importance of search string disclosure is as follows: to determine whether an invention is, in fact, novel, an Examiner searches for earlier inventions ("prior art"). It is general practice at intellectual property offices around the world that the applicant usually sees only the results of the search for earlier inventions, not how the search was done, as the search strings are generally recorded internally. Gaps in the search therefore often surface late, sometimes only when the patent is challenged after grant. Under the new draft Guidelines, Examiners must now disclose their complete search strings in the FER itself. This is a first among major patent offices. For applicants, this means more to respond to in the reply to the examination report, and possibly a point of discussion in any consequent hearings. But it also means weak or incomplete searches can be spotted and challenged early, avoiding unseen hurdles later in the life of the patent.

The Draft also refers to the Biological Diversity Act, 2002, as extensively amended in 2023. Applicants using Indian biological resources, including those deposited outside of India, must keep their details of the sources and geographical origins in order.

The Draft also adds a new depository. Biological material that is not publicly available must be deposited with a recognized International Depository Authority under the Budapest Treaty, and the Draft adds a third Indian option: the National Agriculturally Important Microbial Culture Collection (NAIMCC).

IV. Do these guidelines result in any ease of business?
On the face of the Draft Guidelines, there appears to be no clear relaxation. However, the examples provide genuine clarity. The Draft explains what does not fall within the exclusions under Sections 3(h), 3(i) and 3(p), and it explains divisional applications. On the other hand, the proof required has gone up, especially for inventive step, and particularly for showing enhanced efficacy.

V. What action should businesses take?
Businesses should take charge of pending office actions. They should review pending and future biotech filings against the 36 examples, focusing mainly on the refusal examples, study the court cases cited in the Draft, and prepare arguments that address them in advance.
It must also be kept in mind that these are only Draft Guidelines and not the final guidelines.

VI. Conclusion:
The good news is that the examples in the Draft Guidelines may act as a practical tool for preparing FER replies ahead of time, and diagnostics businesses gain clarity, as well as patent applicants relying on divisional applications and traditional knowledge. The bad news is that the standard of proof has gone up; the cited cases in the Draft Guidelines detail instances where additional evidence is required from the biotechnology patent applicant. Our hope lies in search string disclosure. While it adds work during prosecution, in our view it is good practice, because it brings problems to light early instead of later in the life of a patent. With stakeholders' feedback, the final Guidelines can hopefully provide complete clarity and encourage invention in the critical field of biotechnology.